We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Calls for Novel Endpoints in Buprenorphine Clinical Trials
FDA Guidance Calls for Novel Endpoints in Buprenorphine Clinical Trials
Clinical trials for depot buprenorphine products for opioid dependence treatment should not focus on standard endpoints, but also consider novel efficacy endpoints not directly focused on opioid use, according to new guidance released by the FDA.